Will Imatinib Compromise Reproductive Capacity?

Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conven...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zamah, Alberuni M., Mauro, Michael J., Druker, Brian J., Oktay, Kutluk, Egorin, Merrill J., Cedars, Marcelle I., Rosen, Mitchell P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2011
Konular:
Leukemias
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228060/
https://ncbi.nlm.nih.gov/pubmed/21948652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0137
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller